October 26, 2016
AstraZeneca’s ovarian cancer tablets pass Phase III SOLO-2 trial
AstraZeneca’s Lynparza tablets against BRCA-mutated ovarian cancer have shown…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Sean Bohen
March 23, 2016
AstraZeneca’s Brilianta tablets efficient in prevention of major vascular events
AstraZeneca on Wednesday announced the results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90 mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA)
February 19, 2016
AstraZeneca’s Brilique OK for marketing in EU
The European Commission has granted to AstraZeneca marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.